Skip to main content
Top
Published in: Clinical Rheumatology 10/2011

01-10-2011 | Case Based Review

A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine

Authors: Rachel L. Gross, Jason Brucker, Asena Bahce-Altuntas, Maria A. Abadi, Jules Lipoff, David Kotlyar, Peter Barland, Chaim Putterman

Published in: Clinical Rheumatology | Issue 10/2011

Login to get access

Abstract

In order to describe the clinical and serologic features of a cutaneous vasculitis due to cocaine contaminated with the adulterant levamisole, we report four new cases of this syndrome along with 12 previously reported cases identified through a PubMed Literature search (1964 to March 2011). Of the 16 patients described, the average age was 43, with a female predominance (81% of patients). Over half of patients had involvement of the earlobes, and the rash frequently affected the extremities in a “retiform” pattern. Leukopenia or neutropenia was reported in 56% of patients. Ninety-three percent were anti-neutrophil cytoplasmic antibody positive, and 63% tested positive for anti-phospholipid antibodies. The predominant pattern seen on histopathological examination of the skin was small vessel vasculitis and/or a thrombotic vasculopathy. Treatment in these patients varied widely, with several patients showing improvement or resolution of the rash without specific therapy following cessation of illicit drug use. This new cutaneous vasculitis syndrome can be recognized by its characteristic rash and skin pathology, together with leukopenia and autoantibody production. Certain clinical features can be attributed to the adulterant levamisole, though cocaine as well may play a role in its pathogenesis.
Literature
1.
go back to reference Bhinder S, Majithia V (2007) Cocaine use and its rheumatic manifestations. Clin Rheumatol 26:1192–1194PubMedCrossRef Bhinder S, Majithia V (2007) Cocaine use and its rheumatic manifestations. Clin Rheumatol 26:1192–1194PubMedCrossRef
2.
go back to reference Bradford M, Rosenberg B, Moreno J, Dumyati G (2010) Bilateral necrosis of earlobes and cheeks: another complication of cocaine contaminated with levamisole. Ann Intern Med 152(11):758–759PubMed Bradford M, Rosenberg B, Moreno J, Dumyati G (2010) Bilateral necrosis of earlobes and cheeks: another complication of cocaine contaminated with levamisole. Ann Intern Med 152(11):758–759PubMed
3.
go back to reference Buchanan JA, Vogel JA, Eberhardt AM (2011) Levamisole-induced occlusive necrotizing vasculitis of the ears after use of cocaine contaminated with levamisole. J Med Toxicol 7(1):83–84PubMedCrossRef Buchanan JA, Vogel JA, Eberhardt AM (2011) Levamisole-induced occlusive necrotizing vasculitis of the ears after use of cocaine contaminated with levamisole. J Med Toxicol 7(1):83–84PubMedCrossRef
4.
go back to reference Walsh NMG, Green PJ, Burlingame RW, Pasternak S, Hanly JG (2010) Cocaine-related retiform purpura: evidence to incriminate the adulterant, levamisole. J Cutan Pathol 37(12):1212–1219PubMedCrossRef Walsh NMG, Green PJ, Burlingame RW, Pasternak S, Hanly JG (2010) Cocaine-related retiform purpura: evidence to incriminate the adulterant, levamisole. J Cutan Pathol 37(12):1212–1219PubMedCrossRef
5.
go back to reference Waller JM, Feramisco JD, Alberta-Wszolek L, McCalmont TH, Fox LP (2010) Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit? J Am Acad Dermatol 63(3):530–535PubMedCrossRef Waller JM, Feramisco JD, Alberta-Wszolek L, McCalmont TH, Fox LP (2010) Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit? J Am Acad Dermatol 63(3):530–535PubMedCrossRef
6.
go back to reference Farhat EK, Moorhead TT, Chaffing ML, Douglass MC (2010) Levamisole-induced cutaneous necrosis mimicking coagulopathy. Arch Dermatol 146(11):1320–1321PubMedCrossRef Farhat EK, Moorhead TT, Chaffing ML, Douglass MC (2010) Levamisole-induced cutaneous necrosis mimicking coagulopathy. Arch Dermatol 146(11):1320–1321PubMedCrossRef
7.
go back to reference Click J (2011) Levamisole-induced retiform purpura. J Drug Dermatol 10(2):217 Click J (2011) Levamisole-induced retiform purpura. J Drug Dermatol 10(2):217
8.
go back to reference Geller L, Whang TB, Mercer SE, Phelps R (2011) Retiform purpura: a new stigmata of illicit drug use? Dermatol Online J 17(2):7PubMed Geller L, Whang TB, Mercer SE, Phelps R (2011) Retiform purpura: a new stigmata of illicit drug use? Dermatol Online J 17(2):7PubMed
11.
go back to reference Amery WK, Bruynseels JP (1992) Levamisole, the story and the lessons. Int J Immunopharmacol 14(3):481–486PubMedCrossRef Amery WK, Bruynseels JP (1992) Levamisole, the story and the lessons. Int J Immunopharmacol 14(3):481–486PubMedCrossRef
12.
go back to reference Runge LA, Pinals RS, Lourie SH, Tomar RH (1977) Treatment of rheumatoid arthritis with levamisole. A controlled trial. Arthritis Rheum 20(8):1445–1448PubMedCrossRef Runge LA, Pinals RS, Lourie SH, Tomar RH (1977) Treatment of rheumatoid arthritis with levamisole. A controlled trial. Arthritis Rheum 20(8):1445–1448PubMedCrossRef
13.
go back to reference Christensen KD (1979) Treatment of seronegative spondylarthritis with levamisole: a double-blind placebo-controlled study. Int J Immunopharmacol 1(2):147–150PubMedCrossRef Christensen KD (1979) Treatment of seronegative spondylarthritis with levamisole: a double-blind placebo-controlled study. Int J Immunopharmacol 1(2):147–150PubMedCrossRef
14.
go back to reference Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S (1980) Treatment of nephrotic syndrome with levamisole. J Pediatr 96:490–493PubMedCrossRef Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S (1980) Treatment of nephrotic syndrome with levamisole. J Pediatr 96:490–493PubMedCrossRef
15.
go back to reference Wauwe JV, Janssen PAJ (1991) On the biochemical mode of action of levamisole: an update. Int J Immunopharmacol 13(1):3–9PubMedCrossRef Wauwe JV, Janssen PAJ (1991) On the biochemical mode of action of levamisole: an update. Int J Immunopharmacol 13(1):3–9PubMedCrossRef
16.
go back to reference Chen LY, Lin YL, Chiang BL (2008) Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells. Clin Exp Immunol 151(1):174–181PubMedCrossRef Chen LY, Lin YL, Chiang BL (2008) Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells. Clin Exp Immunol 151(1):174–181PubMedCrossRef
17.
go back to reference Chang A, Osterloh J, Thomas J (2010) Levamisole: a dangerous new adulterant. Clin Pharmacol Ther 88(3):408–411PubMedCrossRef Chang A, Osterloh J, Thomas J (2010) Levamisole: a dangerous new adulterant. Clin Pharmacol Ther 88(3):408–411PubMedCrossRef
19.
go back to reference Valentino AMM, Fuentecilla K (2005) Levamisole: an analytical profile. Microgram J 3(3-4):134–137 Valentino AMM, Fuentecilla K (2005) Levamisole: an analytical profile. Microgram J 3(3-4):134–137
20.
go back to reference Centers for Disease Control and Prevention (CDC) (2009). Agranulocytosis associated with cocaine use—four states, March 2008–November 2009. MMWR 58(49):1381–1385 Centers for Disease Control and Prevention (CDC) (2009). Agranulocytosis associated with cocaine use—four states, March 2008–November 2009. MMWR 58(49):1381–1385
21.
go back to reference Menni S, Gianotti R, Ghio L, Edefonti A (1997) Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient. Pediatr Dermatol 14(6):477–479PubMedCrossRef Menni S, Gianotti R, Ghio L, Edefonti A (1997) Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient. Pediatr Dermatol 14(6):477–479PubMedCrossRef
22.
go back to reference Rongioletti F, Ghio L, Ginervi F et al (1999) Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 140:948–951PubMedCrossRef Rongioletti F, Ghio L, Ginervi F et al (1999) Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 140:948–951PubMedCrossRef
23.
go back to reference Powell J, Grech H, Holder J (2002) A boy with cutaneous necrosis occurring during treatment with levamisole. Clin Exp Dermatol 27(1):32–33PubMedCrossRef Powell J, Grech H, Holder J (2002) A boy with cutaneous necrosis occurring during treatment with levamisole. Clin Exp Dermatol 27(1):32–33PubMedCrossRef
24.
go back to reference Scheinberg MA, Gomes Bezerra JB, Almeida FA, Silveira LA (1978) Cutaneous necrotizing vasculitis induced by levamisole. Br Med J 1(6110):408PubMedCrossRef Scheinberg MA, Gomes Bezerra JB, Almeida FA, Silveira LA (1978) Cutaneous necrotizing vasculitis induced by levamisole. Br Med J 1(6110):408PubMedCrossRef
25.
go back to reference Brewer JD, Meves A, Bostwick M, Hamacher KL, Pittelkow MR (2008) Cocaine abuse: dermatologic manifestations and therapeutic approaches. J Am Acad Dermatol 59(3):483–487PubMedCrossRef Brewer JD, Meves A, Bostwick M, Hamacher KL, Pittelkow MR (2008) Cocaine abuse: dermatologic manifestations and therapeutic approaches. J Am Acad Dermatol 59(3):483–487PubMedCrossRef
26.
27.
28.
go back to reference Williams GT, Johnson SA, Dieppe PA, Huskisson EC (1978) Neutropenia during treatment of rheumatoid arthritis with levamisole. Ann Rheum Dis 37(4):366–369PubMedCrossRef Williams GT, Johnson SA, Dieppe PA, Huskisson EC (1978) Neutropenia during treatment of rheumatoid arthritis with levamisole. Ann Rheum Dis 37(4):366–369PubMedCrossRef
29.
go back to reference Teerenhov L, Heinonen E, Gröhn P, Klefström P, Mehtonen M, Tiilikainen A (1978) High frequency of agranulocytosis in breast-cancer patients treated with levamisole. Lancet 2(8081):151–152CrossRef Teerenhov L, Heinonen E, Gröhn P, Klefström P, Mehtonen M, Tiilikainen A (1978) High frequency of agranulocytosis in breast-cancer patients treated with levamisole. Lancet 2(8081):151–152CrossRef
30.
go back to reference Rosenthal M, Breysse Y, Dixon AS et al (1977) Levamisole and agranulocytosis. Lancet 1(8017):904–905PubMedCrossRef Rosenthal M, Breysse Y, Dixon AS et al (1977) Levamisole and agranulocytosis. Lancet 1(8017):904–905PubMedCrossRef
31.
go back to reference Buchanan JA, Oyer RJ, Patel NR et al (2010) A confirmed case of agranulocytosis after use of cocaine contaminated with levamisole. J Med Toxicol 6:160–164PubMedCrossRef Buchanan JA, Oyer RJ, Patel NR et al (2010) A confirmed case of agranulocytosis after use of cocaine contaminated with levamisole. J Med Toxicol 6:160–164PubMedCrossRef
32.
go back to reference Wiens MO, Son WK, Ross C, Hayden M, Carelton B (2010) Cocaine adulterant linked to neutropenia. CMJA 182(1):57–59CrossRef Wiens MO, Son WK, Ross C, Hayden M, Carelton B (2010) Cocaine adulterant linked to neutropenia. CMJA 182(1):57–59CrossRef
33.
go back to reference Zhu MY, LeGatt DF, Turner AR (2009) Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Int Med 150(4):287–289PubMed Zhu MY, LeGatt DF, Turner AR (2009) Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Int Med 150(4):287–289PubMed
34.
go back to reference Knowles L, Buxton JA, Skuridina N et al (2009) Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduction J 6:30CrossRef Knowles L, Buxton JA, Skuridina N et al (2009) Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduction J 6:30CrossRef
35.
go back to reference Hodinka I, Géher P, Merétey K, Gyódi EK, Petrányi GG, Bozsóky S (1981) Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 65(4):460–464PubMedCrossRef Hodinka I, Géher P, Merétey K, Gyódi EK, Petrányi GG, Bozsóky S (1981) Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 65(4):460–464PubMedCrossRef
36.
37.
go back to reference Czuchlewski DR, Brackney M, Ewers C et al (2010) Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol 133:466–472PubMedCrossRef Czuchlewski DR, Brackney M, Ewers C et al (2010) Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol 133:466–472PubMedCrossRef
38.
go back to reference Neynaber S, Mistry-Burchardi N, Rust C, Samtleben W, Burgdorf WH, Seitz MA, Messer G, Wollenberg A (2008) PR3-ANCA-positive necrotizing multi-organ vasculitis following cocaine abuse. Acta Derm Venereol 88(6):594–596PubMed Neynaber S, Mistry-Burchardi N, Rust C, Samtleben W, Burgdorf WH, Seitz MA, Messer G, Wollenberg A (2008) PR3-ANCA-positive necrotizing multi-organ vasculitis following cocaine abuse. Acta Derm Venereol 88(6):594–596PubMed
39.
go back to reference Fritsma GA, Leikin JB, Maturen AJ, Froelich CJ, Hryhorczuk DO (1991) Detection of anticardiolipin antibody in patients with cocaine abuse. J Emerg Med 9(Suppl 1):37–43PubMedCrossRef Fritsma GA, Leikin JB, Maturen AJ, Froelich CJ, Hryhorczuk DO (1991) Detection of anticardiolipin antibody in patients with cocaine abuse. J Emerg Med 9(Suppl 1):37–43PubMedCrossRef
40.
go back to reference Wiesner O, Russel KA, Lee AS, Jenne DE, Trimarchi M, Gregorini G, Specks U (2004) Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 50(9):2954–2965PubMedCrossRef Wiesner O, Russel KA, Lee AS, Jenne DE, Trimarchi M, Gregorini G, Specks U (2004) Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 50(9):2954–2965PubMedCrossRef
41.
go back to reference Kouassi E, Caille G, Lery L, Larivière L, Vézina M (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamsiole in human plasma and urine. Biopharm Drug Dispos 7(1):71–89PubMedCrossRef Kouassi E, Caille G, Lery L, Larivière L, Vézina M (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamsiole in human plasma and urine. Biopharm Drug Dispos 7(1):71–89PubMedCrossRef
Metadata
Title
A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine
Authors
Rachel L. Gross
Jason Brucker
Asena Bahce-Altuntas
Maria A. Abadi
Jules Lipoff
David Kotlyar
Peter Barland
Chaim Putterman
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 10/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1805-3

Other articles of this Issue 10/2011

Clinical Rheumatology 10/2011 Go to the issue